ReviewToxins2018
Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).
Review in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- High cut-off dialysis mitigates pro-calcific effects of plasma on vascular progenitor cells.Scientific reports · 2021Trial
- Baseline Serum Albumin for Long-Term Risk Stratification in Maintenance Hemodialysis Patients: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Assembled human microbiome and metabolome in chronic kidney disease: Dysbiosis a double-edged sword interlinking Circ-YAP1, Circ-APOE & Circ-SLC8A1.Toxicology reports · 2025Article
- Future of Uremic Toxin Management.Toxins · 2024Review
- Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis.Toxins · 2024Review
- Effects of Dietary Intervention on Nutritional Status in Elderly Individuals with Chronic Kidney Disease.Nutrients · 2024Article
- Inflammation and all-cause mortality in patients undergoing peritoneal dialysis.Einstein (Sao Paulo, Brazil) · 2024Article
- Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney.Clinical kidney journal · 2021Review
- Phosphate, Microbiota and CKD.Nutrients · 2021Review
- The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword.Frontiers in medicine · 2021Review
- Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease.Clinical kidney journal · 2020Article
- The Impact of Inflammatory Profile on Selenium Levels in Hemodialysis Patients.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2020Observational
- Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019Article
- Contribution of the uremic milieu to an increased pro-inflammatory monocytic phenotype in chronic kidney disease.Scientific reports · 2019Article
- Very Low Protein Diet for Patients with Chronic Kidney Disease: Recent Insights.Journal of clinical medicine · 2019Review
- The effect of chronic kidney disease on lipid metabolism.International urology and nephrology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The uremic syndrome, which is the clinical expression of chronic kidney disease (CKD), is a complex amalgam of accelerated aging and organ dysfunctions, whereby cardio-vascular disease plays a capital role. In this narrative review, we offer a summary of the current conservative (medical) treatment options for cardio-vascular and overall morbidity and mortality risk in CKD. Since the progression of CKD is also associated with a higher cardio-vascular risk, we summarize the interventions that may prevent the progression of CKD as well. We pay attention to established therapies, as well as to novel promising options. Approaches that have been considered are not limited to pharmacological approaches but take into account lifestyle measures and diet as well. We took as many randomized controlled hard endpoint outcome trials as possible into account, although observational studies and post hoc analyses were included where appropriate. We also considered health economic aspects. Based on this information, we constructed comprehensive tables summarizing the available therapeutic options and the number and kind of studies (controlled or not, contradictory outcomes or not) with regard to each approach. Our review underscores the scarcity of well-designed large controlled trials in CKD. Nevertheless, based on the controlled and observational data, a therapeutic algorithm can be developed for this complex and multifactorial condition. It is likely that interventions should be aimed at targeting several modifiable factors simultaneously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.